# A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia

> **NCT02055157** · PHASE2 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 35 (actual)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** BMN 111

## Key facts

- **NCT ID:** NCT02055157
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-13
- **Primary completion:** 2017-10-02
- **Final completion:** 2017-10-02
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055157, "A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02055157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*